| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 170,084 | 211,104 | ||
| Short-term investments | 327,750 | 387,645 | ||
| Restricted cash and cash equivalents, current | 2,215 | 88,218 | ||
| Equity investments | 8,679 | 7,270 | ||
| Prepaid expenses and other current assets | 36,956 | 41,469 | ||
| Total current assets | 545,684 | 735,706 | ||
| Intangible assets, net | 7,924 | 7,998 | ||
| Goodwill | 16,937 | 16,937 | ||
| Property and equipment, net | 58,203 | 60,795 | ||
| Operating lease right-of-use assets | 63,555 | 64,853 | ||
| Restricted cash and cash equivalents, noncurrent | 6,957 | 6,956 | ||
| Long-term investments | 304,212 | 286,099 | ||
| Other assets | 15,981 | 13,188 | ||
| Total assets | 1,019,453 | 1,192,532 | ||
| Accounts payable | 6,847 | 12,234 | ||
| Accrued and other liabilities | 68,375 | 82,661 | ||
| Deferred revenue, current | 0 | 10,109 | ||
| Contingent consideration obligation, current | 0 | 0 | ||
| Total current liabilities | 75,222 | 105,004 | ||
| Deferred revenue, noncurrent | 9,433 | - | ||
| Operating lease liabilities, noncurrent | 91,215 | 93,405 | ||
| Contingent consideration obligation, noncurrent | 34,180 | 33,620 | ||
| Other long-term liabilities | 13,305 | 13,031 | ||
| Total liabilities | 223,355 | 245,060 | ||
| Common stock, 0.0001 par value 300,000,000 shares authorized as of september30, 2025 and december31, 2024 139,022,594 and 136,959,446 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 14 | 14 | ||
| Additional paid-in capital | 1,952,843 | 1,941,386 | ||
| Accumulated other comprehensive loss | -1,911 | -2,221 | ||
| Accumulated deficit | -1,154,848 | -991,707 | ||
| Total stockholders equity | 796,098 | 947,472 | ||
| Total liabilities and stockholders equity | 1,019,453 | 1,192,532 | ||
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)